JCR Pharmaceuticals Co., Ltd.
Notice Regarding Revision of Full-Year Consolidated Earnings Guidance
The sales forecast for the fiscal year ending March 2026 has been revised upward to ¥39.5 billion (4.5% increase from previous forecast), while operating income was revised downward to ¥400 million (84.6% decrease), and net income attributable to owners of parent was revised downward to ¥1.6 billion (46.7% decrease).
Key Figures
- Net Sales: ¥39,500 million (4.5% increase from previous forecast)
- Operating Income: ¥400 million (84.6% decrease from previous forecast)
- Net Income Attributable to Owners of Parent: ¥1,600 million (46.7% decrease from previous forecast)
AI要約
Overview of Earnings Forecast Revision
JCR Pharmaceuticals Co., Ltd. has revised its full-year consolidated earnings forecast for the fiscal year ending March 2026. Net sales were revised upward to ¥39.5 billion (an increase of ¥1.7 billion or 4.5%) due to strong performance of treatments for renal anemia and Fabry disease. Conversely, operating income was significantly revised downward to ¥400 million (a decrease of ¥2.2 billion or 84.6%) due to the recording of upfront payments from licensing agreements and increased depreciation expenses. Ordinary income was similarly revised downward to ¥400 million (83.3% decrease), and net income attributable to owners of parent was revised to ¥1.6 billion (a decrease of ¥1.4 billion or 46.7%).
Reasons for Revision and Future Outlook
The increase in net sales is driven by healthy sales of renal anemia and Fabry disease treatments. On the expense side, research and development expenses include an upfront payment of ¥1.5 billion for the exclusive license agreement of givinostat, a treatment for Duchenne muscular dystrophy acquired from Italfarmaco. Additionally, selling, general and administrative expenses increased due to higher depreciation costs for the Kobe Science Park Center. The dividend forecast remains unchanged. The company will continue to monitor market trends closely and strive to improve earnings.
